Because irisin is released from intact myocytes and other organs to protect the energy stores of the ischemic myocardium, we can theoretically consider that irisin levels are decreased in patients with DM who have CAD due to its inadequate release to meet the need for further ATP production. This evidence concerns the gene FNDC5 and coronary artery disorder.